REGULATORY COMPLIANCE – Page 15

Supplier WHO GMP non-compliance during API sourcing – WHO inspector expectations explained

Recognizing the signs of supplier WHO GMP non-compliance is critical for timely interventions. Symptoms can manifest in various ways:Click to read the full article.

Documentation not aligned to WHO during API sourcing – CAPA aligned to WHO standards

Recognizing the early warning signals of misaligned documentation is essential in preventing significant regulatory repercussions. Symptoms may include:Click to read the full article.

Inadequate evidence during inspection during WHO audit – question-and-answer handling techniques

Identifying symptoms of inadequate evidence is critical for timely remedial action. Symptoms can manifest as:Click to read the full article.

Inspection readiness untested during FDA/EMA inspection – preventing escalation to warning letter

Identifying signals that indicate a potential compliance issue during inspections is essential for prompt mitigation. Symptoms may manifest through inconsistent production practices, unexpected deviations in batch records, or discrepancies in…

CAPA follow-up weak during post-inspection response – question-and-answer handling techniques

Recognizing the early signals of a weak CAPA response is critical for immediate action. Here are common symptoms indicating that your CAPA processes may be failing:Click to read the full…

Inspection readiness untested during WHO audit – CAPA closure verification

Playbook for Ensuring Inspection Readiness in Light of WHO Audit Findings As pharmaceutical manufacturing and quality professionals, we face an ongoing challenge in maintaining consistent compliance with regulatory standards. Specifically,…

Team unprepared for interviews during remediation tracking – CAPA closure verification

It is essential to identify early signs that indicate a team may lack preparedness for interviews during remediation tracking. Common symptoms to look for include:Click to read the full article.

Inspection responses delayed before regulatory inspection – evidence pack inspectors expect

Identifying symptoms that indicate potential delays in inspection readiness is crucial. Symptoms may arise from various sources, including documentation practices, manufacturing processes, or even employee training. Common signals to monitor…

Mock audit findings ignored during WHO audit – preventing escalation to warning letter

Recognizing the signs of inadequate mock audit responses is the first step in mitigating risks associated with non-compliance. Here are common symptoms you might observe in production areas or laboratories:Click…

CAPA follow-up weak during remediation tracking – question-and-answer handling techniques

Recognizing early signs of weak CAPA follow-up is crucial to ensuring quality and compliance. Symptoms can manifest in various forms, affecting production outcomes, regulatory inspections, and overall product quality. Key…

Inspection readiness untested during post-inspection response – question-and-answer handling techniques

Symptoms indicating potential issues with inspection readiness can manifest in various ways on the shop floor or within laboratory settings. Recognizing these signals early is crucial for mitigating risks. Here…

CAPA follow-up weak during remediation tracking – preventing escalation to warning letter

Recognizing the early warning signs of weak CAPA follow-up is critical for timely intervention. Here are common symptoms observed in pharmaceutical manufacturing and quality labs:Click to read the full article.